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Objectives: Enhancing thrombus resolution may reduce the long-term complications of venous thrombosis. The aim of
this study was to examine whether a sustained release of vascular endothelial growth factor (VEGF) would further
improve thrombus recanalization.
Methods: Inferior caval vein thrombosis was induced in a cohort of 21 male Wistar rats. A plasmid encoding the human
VEGF gene (phVEGF) was injected directly into thrombus (30 to 50g) and themuscle adjacent to the inferior vena cava
(300 to 400 g). A plasmid containing the gene encoding -galactosidase (pCMV) was injected into the same sites of
a separate cohort of rats to act as a control. Tissues were harvested after 1 and 2 weeks, and -galactosidase activity was
measured to estimate transfection efficiency. Muscle and serum VEGF were measured by enzyme-inked immunosorbent
assay. Thrombus size, recanalization, and organization were determined by computer-assisted image analysis.
Results: The efficiency of control plasmid transfection into muscle was about 1%. No serum hVEGF was detected in
phVEGF- or pCMV-treated animals. Significantly raised levels of hVEGF (P < .01) were detected in the muscle
injected with phVEGF after 2 weeks compared with control muscle. There was a significant reduction in thrombus
size of 23% (P < .05) and 48% (P < .001) in phVEGF-treated animals compared with pCMV-treated controls after
1 and 2 weeks, respectively. Thrombus recanalization was a significantly greater in the phVEGF-treated group after
2 weeks (mean 19%  2% [SEM]) compared with controls (mean 13%  2%, P < .01). There were no differences in the
thrombus organization score.
Conclusion: VEGF gene therapy of venous thrombus resulted in smaller thrombi with greater recanalization. Angiogenic
gene therapy may form the basis of a novel treatment that may improve the resolution of venous thrombi. (J Vasc Surg
2005;42:1183–9.)
Clinical Relevance:Deep vein thrombosis may lead to residual venous obstruction or reflux and result in post-thrombotic
complications that are debilitating and have a substantial socioeconomic impact. Enhancing the resolution of venous
thrombi may reduce post thrombotic complications.Deep vein thrombosis is a common condition, affecting
1% to 2% of the population with an annual incidence of
1:1000.1,2 Between 25% and 75% of patients have residual
venous obstruction or reflux after deep vein thrombosis.3-7
The long-term complications of venous thromboses are leg
swelling, pain, and ulceration, which are common, debili-
tating, and have a large socioeconomic impact. The cost of
treating these conditions in the United Kingdom has been
estimated at £450 million each year.
The changes that lead to the post-thrombotic syn-
drome are caused by a combination of valvular damage and
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doi:10.1016/j.jvs.2005.07.017persistent venous outflow restriction. Valve damage and
subsequent incompetence is not, however, an inevitable
consequence of thrombosis. Veins that recanalize more
rapidly have better preserved valve integrity and a lower
incidence of reflux.8,9 Patients with shorter recanalization
times have been shown to have an improved clinical out-
come,10 and it is therefore reasonable to expect that en-
hancement of thrombus resolution may lead to fewer post-
thrombotic complications.
Anticoagulation is the main form of treatment for
venous thrombosis. This prevents thrombus propagation
and allows slow natural resolution. Thrombolytic agents
remove thrombus rapidly in selected patients with proximal
ileofemoral thrombi who are treated early and can re-
establish luminal patency and maintain distal valve func-
tion. These agents cannot be used in the postoperative
period because of the risk of major bleeding, and they have
not been widely adopted in the United Kingdom.
Natural thrombus resolution occurs by a process of
organization that is similar to that found in wound heal-
ing.11,12 At an early stage, the thrombus is infiltrated with
polymorphonuclear leukocytes, which are later replaced
by monocytes. New endothelial-lined channels, which
then appear within the thrombus,13,14 have a similar
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granulation tissue to deliver oxygen and nutrients to the
hypoxic wound. It is thought that recanalization of the
vein proceeds by the coalescence of these vascular chan-
nels. Influencing these processes may lead to enhanced
resolution of the thrombus.15
Attempts have been made to enhance cellular infiltration
in the hope that this might speed thrombus resolution. Treat-
ment of experimental venous thrombi with interleukin-8, has
been shown to enhance early neovascularization of the throm-
bus.16 Direct injection of monocyte chemotactic protein-1
(MCP-1) into the thrombus has also been shown to stimu-
late thrombus organization.17 It is possible that this effect
may have been the result of MCP-1’s direct angiogenic
activity; or that MCP-1 increased the recruitment of mono-
cytes, which secrete angiogenic cytokines such as human
vascular endothelial growth factor (VEGF165) as they invaded
the thrombus.15
VEGF is a specific endothelial cell mitogen and chemo-
taxin that stimulates in vivo angiogenesis in both peripheral
and myocardial ischemia.18 We have recently shown that a
single bolus of VEGF165 protein injected directly into the
thrombus shortly after its formation results in increased
recanalization and enhanced organization.19 The present
study examined whether a more sustained production of
VEGF, achieved by delivering its gene in an expression
plasmid, would further improve thrombus recanalization
and resolution.
METHODS
Expression plasmids. A 5651-base pair mammalian
expression plasmid, phVEGF, derived from the pUC118
vector and containing the complete human VEGF
(VEGF165) gene (Genentech, South San Francisco,Calif) was
used. Gene transcription was regulated by a cytomegalovirus
(CMV) promoter/enhancer for constitutive expression in
mammalian cells. Media conditioned by human 293 cells
transfected with this plasmid promoted the proliferation of
capillary endothelial cells.20 A similar plasmid constructed
utilizing the same CMV promoter/enhancer and expressing
the gene encoding -galactosidase (pCMV) (Clontech,
Mountain View, Calif) was used as a control. The plasmid was
prepared and purified from Escherichia coli cultures and di-
gested to confirm the presence and size of the inserts.
In vitro assessment of plasmid expression. The
VEGF expression plasmid was assessed in vitro by transfec-
tion of phVEGF into COS-7 cells using the cationic trans-
fection media, DMRIE-C (Invitrogen, Carlsbad, Calif).
Cells were also transfected with pCMV to act as a control.
Cells were cultured in Opti-MEM-1 reduced serum me-
dium (Gibco, Carlsbad, Calif). Human VEGF concentra-
tion was determined by enzyme-linked immunosorbent
assay (ELISA) (R & D Systems, Minneapolis, Minn).
Model of venous thrombus resolution. A previously
described model of venous thrombosis was used.15 Briefly,
21 adult male Wistar rats were anesthetized with inhaled
halothane and subcutaneous buprenorphine. A midline
laparotomy was performed and the inferior vena cava (IVC)was exposed below the renal veins. Flow through the vena
cava was measured by using a 3-mm ultrasonic flow probe
(Linton Instrumentation, Diss, Norfolk, UK). A 4-0 silk
ligature was passed behind the cava and progressively tight-
ened until flow was reduced by 80% to 90% (usually about
1 mL/min). A knot was then tied to maintain constant
flow.
The animal was left anesthetized for 30 minutes to
allow thrombus to form. Plasmid-hVEGF (n  11) or
pCMV (n  10) (30 to 50 g in 10 L of phosphate-
buffered saline [PBS], pH 7.4) was injected over 2 to 3
minutes directly into the thrombus, about 3 mm below the
ligature, by using a 10 L Hamilton syringe fitted with a
33-gauge needle. The small volume of injection was chosen
to minimize the mechanical disruption to the thrombus. As
the needle was withdrawn, a small cotton bud was placed
on the injection site to apply gentle pressure until all
bleeding had stopped. At the same time, a 300- to 400-g
bolus of either phVEGF or pCMV in 250 L of PBS was
injected into the psoas muscle immediately adjacent to the
vena cava by using a 250-LHamilton syringe fitted with a
22-gauge needle. The animals were recovered and allowed
free access to water and normal chow. The study was
performed under the Animals (Scientific Procedures) Act
1986.
Tissue analysis. Tissues were harvested 2 weeks after
thrombus formation and gene therapy. The inferior vena
cava with its contained thrombus and adjacent aorta were
excised, placed in 10% formalin, paraffin-embedded, and
sectioned at intervals along its entire length. Sections were
treated with Martius Scarlet Blue (MSB), which stains
erythrocytes yellow, fresh fibrin red,mature fibrin grey-blue,
and collagen bright blue. Thrombus size (total thrombus
area), recanalization, and organization were measured by us-
ing image analysis as previously described.19
For analysis of recanalization and thrombus organiza-
tion, tissue sections were viewed at 25 magnification
(Leica, Solms, Germany). Digital images were captured by
using a microscope-mounted Coolpix 990 (Nikon, Tokyo,
Japan) digital camera with a resolution of 3.3 megapixels.
Visible recanalization channels (25 m in diameter) were
marked by a blinded observer on the digitized sections
using the Satori Image photo editor (Spaceward Graphics,
Cambridge, UK). These areas were then measured using
Image-Pro Plus image analysis software (Media Cybernet-
ics, Silver Spring,Md). Digital image analysis was calibrated
by capturing an image of a standard 1-mm graticule slide.
All sections through each thrombus were included in
the analysis to allow for variations in recanalization and
organization along the length of the thrombus. The recan-
alization area was taken as a percentage of the vein lumen.
The mean luminal and recanalization areas were compared
between the control and treated animals. In addition, a
series of randomly selected sections with a range of recan-
alization and thrombus areas were analyzed for intraob-
server variability, and a further series was analyzed by a
second blinded observer to determine interobserver vari-
ability.
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cytes. As thrombi organize, the erythrocyte content de-
creases and is replaced by extracellular matrix; thus, the
degree of organization can be assessed by the erythrocyte
content remaining. This was objectively quantified by using
the image analysis software to measure the proportion of
erythrocytes, specifically stained yellow with MSB, in the
thrombus at 25 magnification.
The images were segmented using an 8-bit histogram-
based hue, saturation, and intensity color model. In this
model, pixels are defined by three variables of hue, saturation,
and intensity, each with a value 0 to 255. The hue (color or
wavelength) variable defines the position of the pixel on a
continuous color spectrum; the yellow part of that spectrum
lies between hue values of 10 to 60. Pixels with all values of
saturation (purity of color relative to grey) and intensity (total
brightness) were included. Specific yellow staining of erythro-
cytes and correct segmentation of pixels showing erythro-
cytes were confirmed on high-magnification views. The
results were expressed as an organization score (100 minus
percentage thrombus area). This methodology was vali-
dated by analysis of naturally resolving thrombi of known
ages in this model (linear regression P  .0001; R2, 0.37)
(unpublished data).
Scanning electron microscopy was also carried out on
cross sections of 7-day-old thrombus.
Assessment of plasmid function after
in vivo administration
-Galactosidase activity. Samples of psoas muscle
adjacent to the IVC that had been injected with plasmid
were also excised at the same time that the cava containing
thrombus was harvested. In three control animals, this tissue
was mounted on a cork mat, coated in optimal cutting tem-
perature compound (Miles Scientific, Elkhart, Ind), and snap-
frozen in liquid nitrogen. Frozen 10-m sections were fixed
for 10 minutes with 2% formaldehyde and 0.2% glutaralde-
hyde in PBS saline and rinsed. The slides were then soaked in
staining solution containing X-gal (5-bromo-4-chloro-3-in-
dolyl--D-galactopyranoside, Invitrogen) overnight at 37 oC
in a humidified container. A blue precipitate indicated
-galactosidase activity. The numbers of blue-stained cells
Table I. Vascular endothelial growth factor
concentration in cell culture medium after transfection of
COS7 cells with phVEGF or pCMV expression plasmids
Transfectant n*
VEGF concentration
(ng/ml)
Median Range
Control (untreated) 5 0.06 0.03-0.08
DMRIE/pCMV 4 0.05 0.04-0.06
DMRIE/phVEGF 4 4.60 3.20-5.00
VEGF, Vascular endothelial growth factor; DMRIE, 1,2-dimyristyloxypropyl-
3-dimethyl-hydroxy ethyl ammonium bromide.
*Represents the number of replicate transfections.were counted to estimate transfection efficiency.In the remaining two control samples, the muscle was
homogenized and resuspended in lysis buffer (0.04M -mer-
captoethanol, 0.6 M Na2HPO4, 0.4 M Na2HPO4, 0.1 M
KCl, 0.01MMgSO4, pH 7.0) and subjected to three freeze-
thaw cycles. The homogenate was centrifuged at 13,000g for
10minutes and incubatedwith ortho-nitrophenyl--D-galac-
topyranoside (Invitrogen, -Gal assay kit) at 37oC overnight.
Cleavage of this substrate by -galactosidase activity results
in a yellow color. The reaction was stopped by the addition
of 1 M of sodium carbonate, and the absorbance was
measured at 405 nm.
HumanVEGF levels. All muscle samples treated with
phVEGF were snap-frozen in liquid nitrogen, homoge-
nized and assayed using an ELISA specific for the human
form of VEGF (R&D Systems). ELISA was also used to
measure human VEGF in samples of serum collected from
all animals.
Soluble protein. The soluble protein concentration
of each muscle homogenate was measured by the Coomas-
sie colorimetric method with a bovine serum albumin stan-
dard (Pierce Biotechnology, Rockford, Ill).
Statistical analysis. Results are expressed as median
and range or mean and SEM, and were compared by using
the Mann Whitney U and t tests. P  .05 was considered
significant.
RESULTS
Expression of phVEGF in vitro. COS-7 cells cul-
tured with phVEGF expression plasmid and all types of
transfection vehicle produced detectable hVEGF. There
was no hVEGF detected in cells treated with either pCMV
plasmid or vehicle alone (control cells, Table I).
Transfection efficiency. -Galactosidase activity was
Fig 1. Section of psoas muscle adjacent to the vena cava following
gene therapy with pCMV control plasmid. Myocytes expressing
-galactosidase stained blue (bar  100 m).found in approximately 1% of myocytes in sections taken
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of -galactosidase activity in muscle homogenates was be-
low the sensitivity of the assay employed.
Transfection of VEGF plasmid. At 1 week, there was
an increase in the hVEGF levels measured in muscle treated
with phVEGF (median, 4.1 ng/g soluble protein; range,
1.5 to 7.3) compared with muscle treated with the control
plasmid (median, 1.5 ng/g soluble protein; range, 0.7 to
3.8), but this did not reach statistical significance (P.19)
(Fig 2). Two of the phVEGF-treated muscle samples did,
however, have considerably raised levels of hVEGF (6.6
and 7.3 ng/g soluble protein). At 2 weeks, raised levels of
human VEGF were detected in the muscle injected with
phVEGF (median, 2.7 ng/g soluble protein; range, 1.9 to
5.0) compared with control (median, 1.3 ng/g soluble
protein; range, 1.2 to 1.4, P  .01). No hVEGF was
detected in any serum sample from animals treated with
phVEGF or pCMV plasmids.
Thrombus histology. Recanalization occurred in all
experimental thrombi (Fig 3, a to d). Channels lined by
endothelial-like cells were seen in some animals treated
with the phVEGF, even in poorly organized areas of the
thrombus (Fig 3, e and f).
Thrombus size and recanalization. Thrombus size
and recanalization are expressed as means and SEM (Fig 4).
At one week, mean thrombus area was significantly lower in
phVEGF-treated animals (4.4 mm2  0.25) compared
with controls (5.7 mm2  0.34) (P  .05). Similarly at 2
weeks, the mean thrombus area was significantly lower in
phVEGF-treated animals (1.0 mm2  0.82) compared
with controls (1.9 mm2  0.20) (P  .001).
There was no difference in mean percentage area of the
vein lumen recanalized between treated and control ani-
mals at one week (Fig 4). By 2 weeks, however, there was a
significantly greater percentage area of the vein lumen
recanalized in the phVEGF-treated group compared with
controls (19%  2% vs 13%  2%, P  0.01).
No significant dose-response effect was measured for
Fig 2. Human vascular endothelial growth factor (VEGF) pro-
tein levels in muscle after injection of phVEGF or pCMV control.either thrombus area or recanalization in relation to thedifferences in plasma concentrations injected. There was no
difference in the organization score of thrombi between the
treated and control groups at 1 and 2 weeks (Table II).
DISCUSSION
Rapid pharmacologic removal of thrombus from the deep
veins appears to be associated with fewer post-thrombotic
symptoms and an improved quality of life.21,22 Treatments
that promote the natural process of thrombus resolution
may therefore be expected to reduce long-term complica-
Fig 3. Recanalization during normal and vascular endothelial
growth factor (VEGF)-enhanced thrombus resolution. a, Scan-
ning electron micrographs of cross section of naturally resolving
7- day-old thrombus at the level of the silk ligature (S) shows
evidence of recanalization by the appearance of endothelial-like
cell-lined spaces between the thrombus and vessel wall (b, inset)
(bar  100 m). c, Transverse section of naturally resolving
thrombus shows cell-lined recanalization channels (arrows)
around the organizing thrombus by 7 days. These contain eryth-
rocytes (stained yellow) showing that the channels are in continu-
ity with the circulation (bar  300 m). d, Higher magnification
of thrombus shows cell-lined channels appearing as early as 7 days in
areas of organization (collagen deposition, blue stain)within the body
of the thrombus. These channels also contain erythrocytes, again
suggesting continuity with the circulation (arrows) (bar 100 m).
e, f, Recanalization channels (arrows) forming in otherwise poorly
organized areas of the thrombus contain a high erythrocyte content
in animals treated with the phVEGF plasmid (bar  100 m).tions, particularly in patients who present with long estab-
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Gene therapy with VEGF has already been used to
promote revascularization in the ischemic heart and in
peripheral vascular disease with some success.23-28 We have
demonstrated that sustained VEGF165 release, by transfec-
tion of a plasmid containing the VEGF165 gene, improves
thrombus recanalization and reduces thrombus size in a rat
IVC thrombosis model. Treatment with this plasmid
caused 45% increase in the percentage area of recanaliza-
tion of the thrombus and nearly a halving in the thrombus
size. The increase in recanalization was, however, no
greater than that obtained by treatment with a direct injec-
tion of VEGF165 protein in our previous study.
19 Injection
of VEGF protein in our previous study did not, however,
Fig 4. Effect of phVEGF or control (pCMV) treatment on (a)
thrombus size; and (b) area of recanalization expressed as a per-
centage of vein lumen. Columns show mean and standard error of
mean.result in reduced thrombus size,19 a finding that has beenconfirmed after treatment of the thrombus with other
angiogenic proteins, including basic fibroblast growth fac-
tor (bFGF).28-36,29
In a previous study we injected a bolus of VEGF
protein and observed an increase in thrombus recanaliza-
tion.19 In the current study, plasmid DNA was used to
determine the effect of sustained VEGF production. The
lack of a significant difference in recanalization between the
two delivery methods may have been because of the low
transfection efficiency of the plasmid (approximately 1% of
myocytes). Although this level of transfection is similar to
that reported in other studies,30 it may have resulted in a
low level of VEGF165 production in vivo. The concentra-
tion of VEGF165 in phVEGF treated muscle in this study
was, nevertheless, almost twice as much as found in con-
trols, and the reduction in the thrombus size suggests that
the sustained VEGF165 levels produced were sufficient to
have had an effect on the substance of the thrombus itself.
It could be also argued that the human VEGF165 (gener-
ated by the plasmid used in this study) might not be as
effective as the rat form of VEGF (VEGF164); although
others have successfully used human VEGF165 to promote
angiogenesis in animal tissues.29,31
Circulating VEGF165 could not be detected in any
animal treated with phVEGF. This is in contrast to some
published studies, where VEGF165 protein was detected in
the serum of animals in whom the same plasmid was
injected into the muscle of ischemic limbs25,27 and myo-
cardium.28 It is possible that the ELISA used in this study
was insufficiently sensitive to detect any changes in circu-
lating VEGF165 after phVEGF transfection. Most of the
phVEGFwas injected into themuscle immediately adjacent
to the vena cava, with only 10% to 20% injected into the
thrombus. Skeletal muscle is well recognized as a target
tissue for gene therapy, being easily accessible and having
an excellent blood supply.32 The extensive capillary net-
work around the muscle fibers provides efficient transport
of secreted protein into the circulation. The syncytial na-
ture of muscle fibers means that the transgene can easily
disperse to a large number of neighboring nuclei within the
fiber, which improves transfection efficiency. The protein
produced by the plasmid can act either locally by diffusion
into surrounding tissue or enter the circulation to produce
a systemic effect.
In this study, we have not measured the efficiency of
Table II. Organization scores after injection of phVEGF
or pCMV
pCMV phVEGF
Pn Mean SEM n Mean SEM
1 week 67 55 2.8 62 60 2.4 NS
2 weeks 44 92 1.7 43 93 1.5 NS
VEGF, Vascular endothelial growth factor; SEM, Standard error of mean;
NS, not significant.plasmid transfection into the thrombus or measured the
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experiments with separate muscle and thrombus injections
of plasmid are necessary to determine their relative contri-
butions to VEGF production and thrombus recanalization.
The development of more sophisticated gene expression
reporter systems may also allow us to determine whether
the effect of the plasmid is localized within the thrombus to
the site of injection or whether the effect is more wide-
spread.
Although we could not measure any increase in the
circulating VEGF165 concentration at the time of sampling,
it is possible that there may have been an early rise in
VEGF165 levels that was sufficient to mobilize endothelial
progenitor cells from the bone marrow; or that an unde-
tectable increase in VEGF165 levels may have been suffi-
cient after treatment with phVEGF. These cells have been
shown to contribute to neovascularization in a variety of
conditions33,34 and may also have contributed to recanali-
zation of the thrombus in this study.
The cellular mechanisms that lead to venous thrombus
resolution are still poorly understood. It is well known that
a granulation tissue develops in the thrombus. An initial
infiltration by neutrophils is followed by the recruitment of
large numbers of mononuclear cells (monocytes, endothe-
lial cells, and fibroblasts). The emergence of new vascular
channels within resolving thrombus (recanalization) involves
the formation of pockets and clefts, lined by endothelial-like
cells, appearing at the thrombus-vein wall interface andwithin
the thrombus itself.13,35 The origin of these channels has yet
to be fully elucidated, but it has been suggested that the
capillary network in the vein wall (vasa venora) send capil-
lary buds into the organizing thrombus that anastomose to
form a network of channels.35
The formation of the new channels lined by endothelial-
like cells that occurs as thrombus recanalization begins is,
therefore, analogous to the angiogenic process of in-
growth of capillaries during wound healing. It is unlikely,
however, that the vascular channels are only derived from
the vena venora in the vein wall, as clefts lined by the
endothelial-like cells appear and organization still takes
place (albeit to a lesser degree) when experimental thrombi
are isolated from the wall by an impervious membrane.36
Recanalization and endothelialization is also seen in
thrombus that is placed in a permeable membrane and
exposed to flowing blood but is not in contact with the
vessel wall.37 These data suggest that the thrombus already
contains the cells necessary for organization and recanali-
zation to take place and support the concept that circulat-
ing endothelial cell progenitors may also play an important
part in the recanalization of venous thrombi.38
There is a temporal pattern of both VEGF and bFGF
expression in the thrombus as it resolves, and these are
expressed by invading macrophages.15 The precise stimulus
for the formation of new vascular channels in the thrombus
is, however, not yet known. The macrophages have the
potential to release a range of other angiogenic factors
including angiogenin-1, transforming growth factor-1,
platelet-derived growth factor, tumor necrosis factor-,human growth factor, insulin-like growth factor-1 and
MCP-1, but the concentration and pattern of expression of
many of these factors and the pathways that regulate their
production in the thrombus is unknown. Proteinases re-
leased by these cells can also activate or liberate growth
factors such as bFGF that are trapped in the extracellular
matrix that is laid down as the thrombus organizes. It is
possible that the hypoxia that stimulates angiogenesis in
ischemic tissues may also have a role in the formation of
new vascular channels in the thrombus, but this has yet to
be established.
CONCLUSION
As far as we are aware, this study is the first to attempt
gene therapy to enhance thrombus resolution by promot-
ing recanalization. Thrombus size was halved and recanali-
zation significantly increased by treatment with an expres-
sion plasmid containing the human VEGF gene, but the
molecular and cellular mechanisms that regulate this pro-
cess still need to be elucidated. Enhancing the efficiency of
plasmid transfection or delivery of the VEGF165 gene using
viral transfection vehicles should increase VEGF165 expres-
sion, which might have a greater effect on thrombus size
and recanalization.
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